| Prevalence of cervical cancer screening among women aged 30-49 years (%) WHO | WHO | – |
| People using safely managed drinking water services, urban (% of urban population) World Development Indicators | World Development Indicators | 0% |
| People using safely managed drinking water services (% of population) World Development Indicators | World Development Indicators | 0% |
| Hospital beds (per 1,000 people) World Development Indicators | World Development Indicators | +19% |
| Nurses and midwives (per 1,000 people) World Development Indicators | World Development Indicators | +3.7% |
| Physicians (per 1,000 people) World Development Indicators | World Development Indicators | +3.8% |
| Specialist surgical workforce (per 100,000 population) World Development Indicators | World Development Indicators | – |
| Number of surgical procedures (per 100,000 population) World Development Indicators | World Development Indicators | – |
| Births attended by skilled health staff (% of total) World Development Indicators | World Development Indicators | – |
| Diabetes prevalence (% of population ages 20 to 79) World Development Indicators | World Development Indicators | +7.9% |
| People using safely managed sanitation services, urban (% of urban population) World Development Indicators | World Development Indicators | −0.1% |
| People using safely managed sanitation services (% of population) World Development Indicators | World Development Indicators | −0.1% |
| Tuberculosis treatment success rate (% of new cases) World Development Indicators | World Development Indicators | +3.8% |
| Tuberculosis case detection rate (%, all forms) World Development Indicators | World Development Indicators | 0% |
| Incidence of tuberculosis (per 100,000 people) World Development Indicators | World Development Indicators | −1.5% |
| Mortality rate, adult, female (per 1,000 female adults) World Development Indicators | World Development Indicators | −6.3% |
| Mortality rate, adult, male (per 1,000 male adults) World Development Indicators | World Development Indicators | −8.6% |
| Contraceptive prevalence, any modern method (% of married women ages 15-49) World Development Indicators | World Development Indicators | +49% |
| Contraceptive prevalence, any method (% of married women ages 15-49) World Development Indicators | World Development Indicators | −10.8% |
| Life expectancy at birth, female (years) World Development Indicators | World Development Indicators | +0.1% |
| Life expectancy at birth, total (years) World Development Indicators | World Development Indicators | +0.2% |
| Life expectancy at birth, male (years) World Development Indicators | World Development Indicators | +0.2% |
| Survival to age 65, female (% of cohort) World Development Indicators | World Development Indicators | +0.2% |
| Survival to age 65, male (% of cohort) World Development Indicators | World Development Indicators | +0.5% |
| Population ages 75-79, female (% of female population) World Development Indicators | World Development Indicators | +12.1% |
| Population ages 75-79, male (% of male population) World Development Indicators | World Development Indicators | +11.4% |
| Population ages 80 and above, female (% of female population) World Development Indicators | World Development Indicators | +1.6% |
| Population ages 80 and above, male (% of male population) World Development Indicators | World Development Indicators | +1.7% |
| Pertussis - number of reported cases WHO | WHO | −81.6% |
| Total tetanus - number of reported cases WHO | WHO | 0 |
| Yellow fever - number of reported cases WHO | WHO | 0 |
| Rubella - number of reported cases WHO | WHO | +1 |
| Diphtheria - number of reported cases WHO | WHO | 0 |
| Japanese encephalitis - number of reported cases WHO | WHO | +1 |
| Mumps - number of reported cases WHO | WHO | −2.6% |
| Congenital Rubella Syndrome - number of reported cases WHO | WHO | 0 |
| Neonatal tetanus - number of reported cases WHO | WHO | 0 |
| Measles - number of reported cases WHO | WHO | +11.1% |
| Alcohol, tourist consumption (in litres of pure alcohol), three-year average WHO | WHO | 0% |
| Tuberculosis death rate (per 100,000 people) Health Nutrition and Population Statistics | Health Nutrition and Population Statistics | 0% |
| Number of people pushed below the 60% median consumption poverty line by out-of-pocket health care expenditure Health Nutrition and Population Statistics | Health Nutrition and Population Statistics | – |
| Number of people pushed or further pushed below the $2.15 ($ 2017 PPP) poverty line by out-of-pocket health care expenditure Health Nutrition and Population Statistics | Health Nutrition and Population Statistics | – |
| Number of people pushed or further pushed below the $3.65 ($ 2017 PPP) poverty line by out-of-pocket health care expenditure Health Nutrition and Population Statistics | Health Nutrition and Population Statistics | – |
| Number of people pushed or further pushed below the 60% median consumption poverty line by out-of-pocket health care expenditure Health Nutrition and Population Statistics | Health Nutrition and Population Statistics | – |
| Number of people who are undernourished Health Nutrition and Population Statistics | Health Nutrition and Population Statistics | 0% |
| Population ages 75-79, female Health Nutrition and Population Statistics | Health Nutrition and Population Statistics | +11.8% |
| Population ages 75-79, male Health Nutrition and Population Statistics | Health Nutrition and Population Statistics | +10.9% |
| Population ages 80 and above, female Health Nutrition and Population Statistics | Health Nutrition and Population Statistics | +1.3% |
| Population ages 80 and above, male Health Nutrition and Population Statistics | Health Nutrition and Population Statistics | +1.3% |
| Alcohol, total per capita (15+) consumption (in litres of pure alcohol) (SDG Indicator 3.5.2), three-year average WHO | WHO | 0% |
| Adolescent birth rate (per 1000 women) WHO | WHO | 0 |
| Antimicrobial resistance or decreased susceptibiity (DS/R) to antimicrobials in Neisseria gonorrhoea isolates (WHO-GASP) (proportion) WHO | WHO | – |
| Antimicrobial resistance or decreased susceptibiity (DS/R) to antimicrobials testing in Neisseria gonorrhoea isolates (WHO-GASP) (number) WHO | WHO | – |
| Treatment success rate: XDR-TB cases WHO | WHO | +49.3% |
| HIV-positive TB patients on ART (antiretroviral therapy) (%) WHO | WHO | +5.3% |
| TB patients with known HIV status (%) WHO | WHO | +3.8% |
| Tested TB patients HIV-positive (%) WHO | WHO | −22.8% |
| Treatment success rate for patients treated for MDR-TB (%) WHO | WHO | −22.6% |
| Treatment success rate: new TB cases WHO | WHO | +3.8% |
| Treatment success rate: previously treated TB cases WHO | WHO | −9.5% |
| Treatment success rate: HIV-positive TB cases WHO | WHO | +40% |
| New cases tested for RR-/MDR-TB (%) WHO | WHO | 0% |
| Previously treated cases tested for RR-/MDR-TB (%) WHO | WHO | 0% |
| Cases started on MDR-TB treatment WHO | WHO | −29.6% |
| Confirmed cases of RR-/MDR-TB WHO | WHO | −29.6% |
| Tuberculosis - new and relapse cases WHO | WHO | −0.5% |
| Tuberculosis treatment coverage WHO | WHO | 0% |
| Estimated number of MDR/RR-TB incident cases WHO | WHO | 0% |
| Number of incident tuberculosis cases, (HIV-positive cases) WHO | WHO | −23.1% |
| Incidence of tuberculosis (per 100 000 population per year) WHO | WHO | −1.5% |
| Number of incident tuberculosis cases WHO | WHO | −2% |
| Number of incident tuberculosis cases in children aged 0 - 14 WHO | WHO | – |
| Number of deaths due to tuberculosis, excluding HIV WHO | WHO | 0% |
| Deaths due to tuberculosis among HIV-negative people (per 100 000 population) WHO | WHO | 0% |
| Proportion of bloodstream infection due to Escherichia coli resistant to third-generation cephalosporins (%) WHO | WHO | +1.3% |
| Proportion of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) (%) WHO | WHO | −0.2% |
| Pattern of antibiotic consumption at national level (relative use by AWaRe classification) WHO | WHO | −20.6% |
| Total use of antibacterials expressed as DDD per 1000 inhabitants per day WHO | WHO | +22.7% |
| New or unknown treatment history cases: Pulmonary, bacteriologically confirmed WHO | WHO | +5.5% |
| Incidence of tuberculosis (per 100 000 population) (HIV-positive cases) WHO | WHO | +34.5% |
| Number of people notified with new episode of TB in a given year WHO | WHO | +1.9% |
| Number of people diagnosed with new episode TB who by age group and sex. WHO | WHO | – |
| Number of people diagnosed with new episode of pulmonary TB who are bacteriologically confirmed. WHO | WHO | +2.3% |
| Number of people diagnosed with new episode of pulmonary TB who are clinically diagnosed. WHO | WHO | −0.2% |
| Number of people diagnosed with new episode of pulmonary TB who have extrapulmonary TB. WHO | WHO | +1.9% |
| The number of new and relapse cases of tuberculosis detected in a given year by age and sex WHO | WHO | – |
| The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients. WHO | WHO | +3.6% |
| The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage. WHO | WHO | +0.2% |